{
  "id": 1769622318708,
  "seqId": 164,
  "title": "Mastering Fundus Fluorescein Angiography (FFA)",
  "summary": "A comprehensive guide to Fundus Fluorescein Angiography (FFA), detailing the chemical properties of sodium fluorescein, procedural methods, safety protocols, and the complex morphological interpretation of retinal and choroidal vasculature.",
  "date": "2026-01-28T17:45:18.708Z",
  "data": {
    "title": "Mastering Fundus Fluorescein Angiography (FFA)",
    "summary": "A comprehensive guide to Fundus Fluorescein Angiography (FFA), detailing the chemical properties of sodium fluorescein, procedural methods, safety protocols, and the complex morphological interpretation of retinal and choroidal vasculature.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='40' fill='none' stroke='#0055ff' stroke-width='2'/><circle cx='50' cy='50' r='15' fill='#00ff44' opacity='0.6'/><path d='M20 50 Q 50 20 80 50' fill='none' stroke='#0055ff' stroke-width='1'/><path d='M20 55 Q 50 85 80 55' fill='none' stroke='#0055ff' stroke-width='1'/><path d='M50 10 L 50 25 M 50 75 L 50 90 M 10 50 L 25 50 M 75 50 L 90 50' stroke='#0055ff' stroke-width='2'/></svg>",
    "sections": [
      {
        "title": "The Chemistry of Sodium Fluorescein",
        "icon": "science",
        "type": "mindmap",
        "layout": "half_width",
        "color_theme": "blue",
        "content": {
          "center": "Sodium Fluorescein (C20 H10 O5 Na2)",
          "branches": [
            "Organic, water-soluble dye",
            "Molecular Weight: 376Da",
            "70–85% bound to plasma albumin",
            "Metabolized by the liver",
            "Excreted by the kidneys in 24h"
          ]
        }
      },
      {
        "title": "Optical Properties & Acquisition",
        "icon": "lightbulb",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Stimulation: Blue light (490nm)",
          "Emission: Green light (530nm)",
          "Devices: Fundus cameras or SLO devices",
          "Filters: Spectrally appropriate blue excitation and yellow-green barrier filters",
          "Prerequisites: Clear media and dilated pupils"
        ]
      },
      {
        "title": "Clinical Indications",
        "icon": "assignment_turned_in",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Diagnosis of chorioretinal vascular disease (e.g. diabetic retinopathy, neovascular AMD)",
          "Diagnosis of macular disease (e.g. CSC)",
          "Assessment of intermediate and posterior uveitis",
          "Planning of retinal laser procedures"
        ]
      },
      {
        "title": "Relative Contraindications",
        "icon": "warning",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "A previous history of severe reactions to fluorescein",
          "Pregnancy",
          "Lower doses of fluorescein are advisable for patients with renal impairment"
        ]
      },
      {
        "title": "Side Effects & Adverse Reactions",
        "icon": "report_problem",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "Transient skin and urine discoloration",
          "Extravasation of dye at injection site with local irritation/thrombophlebitis",
          "Nausea and vomiting",
          "Pruritus",
          "Vasovagal syncope (1 in 340)",
          "Severe anaphylaxis (1 in 1,900)",
          "Fatal anaphylaxis (1 in 220,000)"
        ]
      },
      {
        "title": "The Method: Step-by-Step Procedure",
        "icon": "settings",
        "type": "process",
        "layout": "full_width",
        "color_theme": "purple",
        "content": [
          "Step 1: Prepare patient: explain procedure, risks, and benefits, and take formal consent; dilate; check blood pressure (BP); cannulate (medium-/largebore vein); ensure resuscitation facilities (including ‘crash’ trolley) are readily available.",
          "Step 2: Seat patient at camera, and adjust height for patient comfort and camera alignment. Ask patient to fix on the fixation target.",
          "Step 3: Take colour and ‘red-free’ fundal photographs.",
          "Step 4: Inject fluorescein (5ml of 10% IV), and take early rapid sequence photographs (at about 1s intervals for 25–30s).",
          "Step 5: Continue less frequent shots, alternating between eyes for up to 5–10min. late images may be taken at 10–20min."
        ]
      },
      {
        "title": "Critical Timing: The Early Phase",
        "icon": "priority_high",
        "type": "remember",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": {
          "mnemonic": "PRIORITY EYE",
          "explanation": "The early shots are critical: it is generally only possible to get a good series of early shots from one eye due to the time it takes to move between eyes. It is therefore important that the photographer is informed which eye takes priority."
        }
      },
      {
        "title": "Sequential Interpretation Phases",
        "icon": "restore_page",
        "type": "process",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "1. Choroidal (prearterial)",
          "2. Arterial",
          "3. Capillary",
          "4. Venous",
          "5. Late"
        ]
      },
      {
        "title": "Box 2.1: Reporting an FFA",
        "icon": "fact_check",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "purple",
        "content": [
          "Report the red-free photo",
          "Specify the phase",
          "Note hyper- and hypofluorescence and any delay in filling (see Table 2.5)",
          "Note distinctive features (petalloid, smoke stack, etc.)",
          "Note any change in area, intensity, or fluorescence over time",
          "FFAs should be read sequentially, according to their phases (choroidal to late)",
          "This test should be reported in conjunction with patient history and examination"
        ]
      },
      {
        "title": "Table 2.5: Morphological Analysis - Hyperfluorescence",
        "icon": "visibility",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Feature",
            "Common Causes"
          ],
          "rows": [
            [
              "Window defect",
              "RPE defect (e.g. RPE atrophy, macular hole)"
            ],
            [
              "Leakage of dye",
              "At macula: cystoid macular oedema (CMO) (petalloid appearance), other macular oedema. At disc: papilloedema, ischaemic optic neuropathy, inflammation. Elsewhere: new retinal vessels, vasculitis, choroidal neovascularization (CNV)"
            ],
            [
              "Pooling of dye",
              "Detachment of the neural retina or RPE (e.g. central serous chorioretinopathy (CSC), AMD)"
            ],
            [
              "Staining of dye",
              "Drusen, disc, disciform scars, sclera (seen if overlying chorioretinal atrophy/thinning)"
            ],
            [
              "Abnormal vessels",
              "Tumours (haemangiomas, melanomas, etc.)"
            ],
            [
              "Autofluorescence (visible without dye)",
              "Disc drusen, large lipofuscin deposits"
            ]
          ]
        }
      },
      {
        "title": "Table 2.5: Morphological Analysis - Hypofluorescence",
        "icon": "visibility_off",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Feature",
            "Common Causes"
          ],
          "rows": [
            [
              "Transmission defect: Preretinal",
              "Blocks view of retinal and choroidal circulations: media opacity, especially vitreous opacities (inflammation, haemorrhage, degenerative), preretinal haemorrhage"
            ],
            [
              "Transmission defect: Inner retinal",
              "Blocks view of capillary circulation, but larger retinal vessels seen: dot and blot haemorrhages (e.g. vein occlusion), intraretinal lipid (e.g. diabetic retinopathy)"
            ],
            [
              "Transmission defect: Prechoroidal",
              "Blocks view of choroidal circulation, but retinal circulation seen: subretinal haemorrhage, pigment (e.g. choroidal naevi, congenital hypertrophy of the retinal pigment epithelium (CHRPE), melanoma), lipid, lipofuscin"
            ],
            [
              "Filling defects: Retinal arteriolar non-perfusion",
              "e.g. arterial occlusion"
            ],
            [
              "Filling defects: Retinal capillary non-perfusion",
              "e.g. ischaemia 2° to diabetes, vein occlusion"
            ],
            [
              "Filling defects: Choroidal non-perfusion",
              "e.g. infarcts 2° to accelerated hypertension, etc."
            ],
            [
              "Filling defects: Disc non-perfusion",
              "e.g. ischaemic optic neuropathy"
            ]
          ]
        }
      },
      {
        "title": "Reference & Source Info",
        "icon": "info",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Fun D u S F lu ORESCEI n A n GIOGRAP h Y (FFA) 71. This organic, water-soluble dye aids visualization of the choroidal and retinal vasculature. Sodium fluorescein (weight 376Da) is 70–85% bound to plasma albumin, metabolized by the liver, and excreted by the kidneys in 24h. Visualization requires clear media and dilated pupils."
      }
    ],
    "chapterId": "investigations"
  },
  "chapterId": "investigations",
  "_newlyImported": 1769622318708,
  "communityId": "sub_1769618268159_yx3o1vq00xsvku",
  "communityAuthor": "Dodiii",
  "communityDate": "2026-01-28T16:37:48.159Z"
}